Selective toxicity of glycyrrhetinic acid against tumorigenic r/m HM-SFME-1 cells is potentially attributed to downregulation of glutathione

Biochimie

Volumn 93, Issue 7, 2011, Pages 1172-1178

  Yamaguchi, H ^a   Yu, T ^a   Kidachi, Y ^a   Akitaya, T ^a   Yoshida, K ^a   Kamiie, K ^a   Noshita, T ^a   Umetsu, H ^a   Ryoyama, K ^a  

^a MEIJO UNIVERSITY   (Japan)

Author keywords

11 hydroxysteroid dehydrogenase type 2 (11 HSD2); Glutathione (GSH); Glycyrrhetinic acid (GA); Human c Ha ras and mouse c myc cotransfected highly metastatic serum free mouse embryo 1 (r m HM SFME 1); Molecular modeling

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ACETYLCYSTEINE; BUTHIONINE SULFOXIMINE; DOXORUBICIN; GLUTATHIONE; GLYCYRRHETINIC ACID; MANUMYCIN; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; GLYCYRRHIZA; ONCOGENE C H RAS; ONCOGENE C MYC; OXIDATION REDUCTION STATE; TUMOR CELL; UPREGULATION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ACETYLCYSTEINE; ANIMALS; ANTI-INFLAMMATORY AGENTS; BUTHIONINE SULFOXIMINE; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FREE RADICAL SCAVENGERS; GLUTATHIONE; GLYCYRRHETINIC ACID; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NEOPLASMS; OXIDATION-REDUCTION; PROTEIN BINDING; PROTEIN CONFORMATION; REACTIVE OXYGEN SPECIES; UP-REGULATION;

GLYCYRRHIZA;

EID: 79958040987     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2011.04.011     Document Type: Article

References (47)

1. R.B. Weiss, The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol. 19 (1992) 670-686. (Pubitemid 23004844)
2. D.A. Gewirtz, A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin, Biochem. Pharmacol. 57 (1999) 727-741.
3. M.A. Frassanito, A. Cusmai, C. Piccoli, F. Dammacco, Manumycin inhibits farnesyltransferase and induces apoptosis of drug-resistant interleukin 6- producing myeloma cells, Br. J. Haematol. 118 (2002) 157-165.
4. O. Kainuma, T. Asano, M. Hasegawa, T. Kenmochi, T. Nakagohri, Y. Tokoro, K. Isono, Inhibition of growth and invasive activity of human pancreatic cancer cells by a farnesyltransferase inhibitor, manumycin, Pancreas 15 (1997) 379-383. (Pubitemid 27525634)
5. J.M. Zhou, X.F. Zhu, Q.C. Pan, D.F. Liao, Z.M. Li, Z.C. Liu, Manumycin induces apoptosis in human hepatocellular carcinoma HepG2 cells, Int. J. Mol. Med. 12 (2003) 955-959.
6. J. Pan, S.C. Yeung, Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors, Cancer Res. 65 (2005) 9109-9112. (Pubitemid 41507967)
7. R. Martin, J. Carvalho, E. Ibeas, M. Hernandez, V. Ruiz-Gutierrez, M.L. Niet, Acidic triterpenes compromise growth and survival of astrocytoma cell lines by regulating reactive oxygen species accumulation, Cancer Res. 67 (2007) 3741-3751. (Pubitemid 46762160)
8. M. Nihal, N. Ahmad, H. Mukhtar, G.S. Wood, Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma, Int. J. Cancer 114 (2005) 513-521. (Pubitemid 40349609)
9. H. Yamaguchi, T. Noshita, Y. Kidachi, H. Umetsu, M. Hayashi, K. Komiyama, S. Funayama, K. Ryoyama, Isolation of ursolic acid from apple peels and its specific efficacy as a potent antitumor agent, J. Health Sci. 54 (2008) 654-660. (Pubitemid 352791998)
10. H. Yamaguchi, Y. Kidachi, K. Kamiie, T. Noshita, H. Umetsu, K. Ryoyama, Glycyrrhetinic acid induces anoikis-like death and cytoskeletal disruption in the central nervous system tumorigenic cells, Biol. Pharm. Bull. 33 (2010) 321-324.
11. H. Yamaguchi, T. Noshita, T. Yu, Y. Kidachi, K. Kamiie, H. Umetsu, K. Ryoyama, Novel effects of glycyrrhetinic acid on the central nervous system tumorigenic progenitor cells: induction of actin disruption and tumor cell-selective toxicity, Eur. J. Med. Chem. 45 (2010) 2943-2948.
12. T. Yu, H. Yamaguchi, T. Noshita, Y. Kidachi, H. Umetsu, K. Ryoyama, Selective cytotoxicity of glycyrrhetinic acid against tumorigenic r/m HM-SFME-1 cells: potential involvement of H-Ras downregulation, Toxicol. Lett. 192 (2010) 425-430.
13. D.T. Loo, J.I. Fuquay, C.L. Rawson, D.W. Barnes, Extended culture of mouse embryo cells without senescence: inhibition by serum, Science 236 (1987) 200-202. (Pubitemid 17061040)
14. D. Loo, C. Rawson, A. Helmrich, D. Barnes, Serum-free mouse embryo (SFME) cells: growth responses in vitro, J. Cell. Physiol. 139 (1989) 484-491.
15. C. Rawson, C. Cosola-Smith, D. Barnes, Death of serum-free mouse embryo cells caused by epidermal growth factor deprivation is prevented by cycloheximide, 12-O-tetradecanoylphorbol-13-acetate, or vanadate, Exp. Cell Res. 186 (1990) 177-181.
16. C. Rawson, S. Shirahata, P. Collodi, T. Natsuno, D. Barnes, Oncogene transformation frequency of nonsenescent SFME cells is increased by c-myc, Oncogene 6 (1991) 487-489. (Pubitemid 21924109)
17. T. Nomura, S. Matano, G. Okada, H. Tokuyama, I. Hori, S. Nakamura, T. Kameyama, K. Ryoyama, Establishment of a metastatic murine cell line carrying the human c-Ha-ras, In Vitro Cell. Dev. Biol. 29A (1993) 614-616.
18. A.L. Albiston, V.R. Obeyesekere, R.E. Smith, Z.S. Krozowski, Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme, Mol. Cell. Endocrinol. 105 (1994) R11-R17.
19. T. Nigawara, Y. Iwasaki, M. Asai, M. Yoshida, M. Kambayashi, H. Sashinami, K. Hashimoto, T. Suda, Inhibition of 11β-hydroxysteroid dehydrogenase eliminates impaired glucocorticoid suppression and induces apoptosis in corticotroph tumor cells, Endocrinology 147 (2006) 769-772. (Pubitemid 43112993)
20. K. Koyama, K. Myles, R. Smith, Z. Krozowski, Expression of the 11β-hydroxysteroid dehydrogenase type II enzyme in breast tumors and modulation of activity and cell growth in PMC42 cells, J. Steroid Biochem. Mol. Biol. 76 (2001) 153-159. (Pubitemid 32510677)
21. P.G. Cohen, Estradiol induced inhibition of 11β-hydroxysteroid dehydrogenase 1: an explanation for the postmenopausal hormone replacement therapy effects, Med. Hypotheses 64 (2005) 989-991. (Pubitemid 40385956)
22. S. Zbankova, J. Bryndova, M. Kment, J. Pacha, Expression of 11β-hydroxysteroid dehydrogenase types 1 and 2 in colorectal cancer, Cancer Lett. 210 (2004) 95-100. (Pubitemid 38692593)
23. D. Trachootham, Y. Zhou, H. Zhang, Y. Demizu, Z. Chen, H. Pelicano, P.J. Chiao, G. Achanta, R.B. Arlinghaus, J. Liu, P. Huang, Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate, Cancer Cell 10 (2006) 241-252. (Pubitemid 44311067)
24. R.G. Ham, W.L. McKeehan, Media and growth requirements, Methods Enzymol. 58 (1979) 44-93.
25. J.P. Mather, G.H. Sato, The use of hormone-supplemented serum-free media in primary cultures, Exp. Cell Res. 124 (1979) 215-221.
26. J. Carmichael, W.G. DeGraff, A.F. Gazdar, J.D. Minna, J.B. Mitchell, Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity, Cancer Res. 47 (1987) 943-946. (Pubitemid 17027906)
27. 2+ channels: a possible involvement of free radicals, J. Neurochem. 68 (1997) 265-271.
28. M. Levitt, Accurate modeling of protein conformation by automatic segment matching, J. Mol. Biol. 226 (1992) 507-533.
29. T. Fechteler, U. Dengler, D. Schomberg, Prediction of protein three-dimensional structures in insertion and deletion regions: a procedure for searching data bases of representative protein fragments using geometric scoring criteria, J. Mol. Biol. 253 (1995) 114-131.
30. J. Goto, R. Kataoka, H. Muta, N. Hirayama, ASEDock-Docking based on alpha spheres and excluded volumes, J. Chem. Inf. Model. 48 (2008) 583-590. (Pubitemid 351535426)
31. T.A. Halgren, Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94, J. Comput. Chem. 17 (1996) 490-519.
32. K.T. Liby, M.M. Yore, M.B. Sporn, Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer, Nat. Rev. Cancer 7 (2007) 357-369.
33. 3 integrin-mediated drug resistance in human laryngeal carcinoma cells is caused by glutathione-dependent elimination of drug-induced reactive oxidative species, Mol. Pharmacol. 74 (2008) 298-306.
34. K.T. Sears, H. Daino, G.B. Carey, Reactive oxygen species-dependent destruction of MEK and Akt in manumycin stimulated death of lymphoid tumor and myeloma cell lines, Int. J. Cancer 122 (2008) 1496-1505. (Pubitemid 351294957)
35. A. Lupetti, A. Paulusma-Annema, S. Senesi, M. Campa, J.T. Van Dissel, P.H. Nibbering, Internal thiols and reactive oxygen species in candidacidal activity exerted by an N-terminal peptide of human lactoferrin, Antimicrob. Agents Chemother. 46 (2002) 1634-1639.
36. J.M. Estrela, A. Ortega, E. Obrador, Glutathione in cancer biology and therapy, Crit. Rev. Clin. Lab. Sci. 43 (2006) 143-181. (Pubitemid 43860449)
37. H. Hentze, I. Schmitz, M. Latta, A. Krueger, P.H. Krammer, A. Wendel, Glutathione dependence of caspase-8 activation at the death-inducing signaling complex, J. Biol. Chem. 277 (2002) 5588-5595.
38. N. Mirkovic, D.W. Voehringer, M.D. Story, D.J. McConkey, T.J. McDonnell, R.E. Meyn, Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols, Oncogene 15 (1997) 1461-1470. (Pubitemid 27437836)
39. G.M. Enns, The contribution of mitochondria to common disorders, Mol. Genet. Metab. 80 (2003) 11-26. (Pubitemid 37272232)
40. B.R. Walker, J.C. Campbell, B.C. Williams, C.R. Edwards, Tissue-specific distribution of the NAD(+)-dependent isoform of 11β-hydroxysteroid dehydrogenase, Endocrinology 131 (1992) 970-972.
41. A.K. Agarwal, T. Mune, C. Monder, P.C. White, Cloning of cDNA encoding an NAD(+)-dependent isoform of 11β-hydroxysteroid dehydrogenase in sheep kidney, Endocr. Res. 21 (1995) 389-397.
42. M.Z. Zhang, J. Xu, B. Yao, H. Yin, Q. Cai, M.J. Shrubsole, X. Chen, V. Kon, W. Zheng, A. Pozzi, R.C. Harris, Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans, J. Clin. Invest. 119 (2009) 876-885.
43. N. Tewari-Singh, C. Agarwal, J. Huang, B.J. Day, C.W. White, R. Agarwal, Efficacy of glutathione in ameliorating sulfur mustard analog-induced toxicity in cultured skin epidermal cells and in SKH-1 mouse skin in vivo, J. Pharmacol. Exp. Ther. 336 (2011) 450-459.
44. R. Ren, Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia, Nat. Rev. Cancer 5 (2005) 172-183.
45. J. Couzin, Cancer drugs. Smart weapons prove tough to design, Science 298 (2002) 522-525.
46. S. Frantz, Drug discovery: playing dirty, Nature 437 (2005) 942-943.
47. M. Saleem, N. Maddodi, M. Abu Zaid, N. Khan, B. bin Hafeez, M. Asim, Y. Suh, J.M. Yun, V. Setaluri, H. Mukhtar, Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis, Clin. Cancer Res. 14 (2008) 2119-2127.